Afatinib Dimaleate

GILOTRIF®

Antineoplastic landscape

About GILOTRIF®

  1. Marketed by Boehringer Ingelheim Pharmaceuticals, Inc
  2. Orally bioavailable anilino-quinazoline derivative and inhibitor of the receptor tyrosine kinase (RTK) epidermal growth factor receptor (ErbB; EGFR) family
  3. First-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have non-resistant epidermal growth factor receptor (EGFR) mutations

Approvals

  1. First U.S. approval: July 12, 2013
  2. First E.U. approval: September 25, 2013

Constraint date forecast:

  1. Patent expiry: 2026 (United States)
  2. SPC expiry: 2026 (European Union)
  3. Patent expiry: 2026 (Japan)

API availability

Source: Cortellis Generics Intelligence

The future of the generics landscape

Drugs to Watch
Drugs to Watch
Drugs to Watch
Drugs to Watch

From innovation to bottom line

Access our global intelligence, advanced analytics and global team of experts.

Contact our team